复方蝉花片对2型糖尿病患者的临床疗效及安全性评价

目的评价复方蝉花片对2型糖尿病患者的治疗作用及安全性评价。方法选择中国人民解放军第二四五医院血糖偏高的成年2型糖尿病患者109例,随机分为2组,对照组(n=54)采用常规治疗,治疗组(n=55)在常规治疗基础上口服复方蝉花片2片/次、2次/d,服用量2.4 g/d,连续服用2个月,评价其疗效与安全性。结果两组治疗前空腹血糖、餐后2 h血糖、尿糖比较无差异。治疗后,两组空腹血糖、尿糖均较治疗前降低,治疗组餐后2 h血糖降低;治疗组空腹血糖降低率(13.50±6.71)%与对照组比较差异显著(P<0.01)、餐后2 h血糖降低率(13.85±8.74)%,与对照组比较差异显著(P<0.01);治疗组尿糖积分下降率72.2%,对照组尿糖积分下降率10.52%,两组比较差异有显著性(P<0.001);且两组无不良反应发生。结论复方蝉花片对于2型糖尿病患者具有治疗作用,且比较安全,值得推广应用及深入开发。

Clinical efficacy and safety evaluation of Compound Cicada Flower Tablets on patients with type 2 diabetes

Objective To evaluate the clinical effect and safety of Compound Cicada Flower Tablets on patients with type 2 diabetes Methods One hundrend and nine patients with type 2 diabetes mellitus(DM) who had high blood glucose in the 245 th Hospital of the Chinese People’s Liberation Army were randomly divided into 2 groups. The control group(n = 54) received conventional treatment and treatment group(n = 55) received onventional treatment and oral administration Compound Cicada Flower Tablets 2 tablets/times, 2 times/d, taking a dose of 2.4 g/d, and taking it continuously for 2 months to evaluate its efficacy and safety. Results There was no difference in fasting blood glucose, blood glucose 2 h after meal, and urine glucose between two groups. After treatment, the fasting blood glucose and urine glucose of two groups were lower than those of before treatment, and the blood glucose 2 h after meal of ttreatment group was lowered. The freduction rate of asting blood glucose in treatment group was(13.50 ±6.71)%, significantly different from the control group(P < 0.01), and the reduction rate of blood glucose 2 h after meal in treatment group was(13.85 ± 8.74)%, significantly different from ontrol group(P < 0.01). The decrease rate of urine glucose score in the treatment group and the control group were 72.2% and 10.52%, respectively and there was a significant difference between the two groups(P < 0.001);and no adverse reactions occurred in the two groups. Conclusion The Compound Cicada Flower Tablet is an clinical therapy for patients with type 2 diabetes, and it is safer, and it is worthy of promotion and further development.